The ConsiGma® continuous tableting line is a multipurpose platform that has been designed to transfer powder into coated tablets in development, pilot, clinical and production volumes in a single compact unit. The system can perform dosing and mixing of raw materials, wet or dry granulation, drying, tableting, coating and quality control, all in one line. From powder to coated tablet, ConsiGma® allows pharmaceutical companies to continuously process and manufacture oral solid dosage forms. Offering significant reductions in development time and raw material (API) use, process and energy costs can be considerably decreased using this groundbreaking technology while maintaining quality and increasing manufacturing efficiency. Headquartered in northwest UK, Perceptive Engineering specializes in the deployment of model-based APC, especially within the pharmaceutical sector. Perceptive’s PharmaMV™ platform provides modular tools to design, deploy and maintain advanced applications within a regulated environment.
The partnership builds on the successful implementation of Perceptive’s APC platform into the first-generation PCMM (portable, continuous, miniature and modular) platform for the development and production of pharmaceutical OSDs. Originally conceived in conjunction with Pfizer and G-CON, the three companies formed a consortium to design and build a portable, autonomous manufacturing environment for continuous OSD production using GEA’s ConsiGma® 25 equipment and G-CON's modular POD system. A prototype unit is currently being implemented at Pfizer’s labs in Groton (Connecticut, USA).
This collaboration also builds on the previously announced relationship between GEA and Siemens, as well as the existing association between Siemens and Perceptive. Together, this provides a leading-edge, industrially proven solution for pharmaceutical manufacturers, comprising both hardware and software platforms, as well as PAT integration, process monitoring, process analytics, control and optimization. This complete, seamless suite is designed to help pharma companies exploit the opportunities presented by moving to continuous manufacturing.
Commenting on the announcement, GEA’s Phillip Gabb, Head of Solid Dosage Sales Support, said: “With collaborations such as this one, GEA and its partners are leading the way toward smaller, more flexible continuous processing technologies that have the potential to transform the future of pharmaceutical development and manufacturing — and deliver customized quantities of drugs to patients in need in a quick and efficient way.”
During the upcoming ACHEMA trade show, taking place in Frankfurt, Germany, GEA will hold a press conference on Tuesday 12 June at 11 AM in Hall 4.0 (stand F46) to announce a number of industry collaborations that will help to facilitate the uptake of continuous manufacturing technology in the drug production sector.
We are actively building collaborative partnerships with providers of complementary technologies and solutions, which are not within GEA’s scope of supply, to deliver the services and infrastructure our customers need to be able to implement continuous manufacturing, noted Phil.
About Perceptive Engineering’s Technology
Perceptive Engineering creates engineering solutions using model-based control and monitoring technologies. Their PharmaMVTM software platform is specifically designed to support development and deployment of multivariable technologies within the regulated pharmaceutical production environment. It uses a digital model of the process plant to assist with operational decisions. Running the model “live,” in parallel with the process, is designed to verify the process continues to operate at an optimum efficiency.
PharmaMV™ detects differences between the model and the process; these are highlighted to control room personnel and used within a control system to regulate the process. These systems also provide early warning of any developing faults, within the process, equipment and analytical devices, thereby forming an integral part of a Continuous Process Verification (CPV) system.
PharmaMV can be embedded within GEA’s automation infrastructure to provide a seamless environment for control room personnel. The APC methods are controlled by the process recipe management system with embedded multivariate visualization tools and CPV reports provided.
GEA Group Aktiengesellschaft
Peter-Müller-Str. 12
40468 Düsseldorf
Germany
Tel +49 211 9136-0
GEA is one of the world's largest suppliers of systems and components to the food, beverage and pharmaceutical industries. The international technology¬ group, founded in 1881, focuses on machinery and plants, as well as advanced process technology, components, and comprehensive services.
With more than 18,000 employees working across five divisions and 62 countries, the group generated revenues of more than EUR 4.7 billion in fiscal year 2021. GEA plants, processes, components and services enhance the efficiency and sustainability of production processes across the globe. They contribute significantly to the reduction of CO2 emissions, plastic usage and food waste. In doing so, GEA makes a key contribution toward a sustainable future, in line with the company’s purpose: "Engineering for a better world". GEA is listed in the German MDAX and the STOXX® Europe 600 Index and is also among the companies comprising the DAX 50 ESG and MSCI Global Sustainability Indices.
Stay in touch with GEA innovations and stories by signing up for news from GEA.
Sign upWe are here to help! With just a few details we will be able to respond to your inquiry.
Contact us